-
1
-
-
68049140789
-
Cancer pharmacoethnicity: Ethnic differences in susceptibility to the effects of chemotherapy
-
O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009;15:4806-14.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4806-4814
-
-
O'Donnell, P.H.1
Dolan, M.E.2
-
2
-
-
58849149494
-
Pharmacogenetics and pharmacogenomics of anticancer agents
-
Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009;59:42-55.
-
(2009)
CA Cancer J Clin
, vol.59
, pp. 42-55
-
-
Huang, R.S.1
Ratain, M.J.2
-
3
-
-
49949087028
-
Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice
-
Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 2008;84:287-94.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 287-294
-
-
Huang, S.M.1
Temple, R.2
-
4
-
-
43749114271
-
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group
-
Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008;26:2131-8.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2131-2138
-
-
Schwab, M.1
Zanger, U.M.2
Marx, C.3
Schaeffeler, E.4
Klein, K.5
Dippon, J.6
-
5
-
-
4444339951
-
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy
-
Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004;10:5880-8.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5880-5888
-
-
Lecomte, T.1
Ferraz, J.M.2
Zinzindohoué, F.3
Loriot, M.A.4
Tregouet, D.A.5
Landi, B.6
-
6
-
-
0033564283
-
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations
-
Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999; 58:310-2.
-
(1999)
Genomics
, vol.58
, pp. 310-312
-
-
Marsh, S.1
Collie-Duguid, E.S.2
Li, T.3
Liu, X.4
McLeod, H.L.5
-
7
-
-
34250644339
-
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients
-
Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 2007;8:567-75.
-
(2007)
Pharmacogenomics
, vol.8
, pp. 567-575
-
-
Lal, S.1
Wong, Z.W.2
Jada, S.R.3
Xiang, X.4
Chen, S.X.5
Ang, P.C.6
-
8
-
-
24944566839
-
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer
-
Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005;23:6117-25.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6117-6125
-
-
Petros, W.P.1
Hopkins, P.J.2
Spruill, S.3
Broadwater, G.4
Vredenburgh, J.J.5
Colvin, O.M.6
-
9
-
-
40449138996
-
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients
-
Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008;50:769-71.
-
(2008)
Pediatr Blood Cancer
, vol.50
, pp. 769-771
-
-
Renbarger, J.L.1
McCammack, K.C.2
Rouse, C.E.3
Hall, S.D.4
-
10
-
-
34250202527
-
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1*6 and *28
-
Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007;17:497-504.
-
(2007)
Pharmacogenet Genomics
, vol.17
, pp. 497-504
-
-
Minami, H.1
Sai, K.2
Saeki, M.3
Saito, Y.4
Ozawa, S.5
Suzuki, K.6
-
11
-
-
66849111193
-
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
-
Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27:2604-14.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2604-2614
-
-
Innocenti, F.1
Kroetz, D.L.2
Schuetz, E.3
Dolan, M.E.4
Ramírez, J.5
Relling, M.6
-
12
-
-
79958118813
-
Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: Results of a meta-analysis of randomized controlled trials
-
Soo RA, Loh M, Mok TS, Ou SH, Cho BC, Yeo WL, et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J Thorac Oncol 2011;6:1030-8.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1030-1038
-
-
Soo, R.A.1
Loh, M.2
Mok, T.S.3
Ou, S.H.4
Cho, B.C.5
Yeo, W.L.6
-
13
-
-
20844450219
-
EGFR mutation and response of lung cancer to gefitinib
-
Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 2005;352:2136.
-
N Engl J Med
, vol.2005
, pp. 352
-
-
Toyooka, S.1
Kiura, K.2
Mitsudomi, T.3
-
14
-
-
70249137644
-
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics
-
Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-6.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3540-3546
-
-
Gandara, D.R.1
Kawaguchi, T.2
Crowley, J.3
Moon, J.4
Furuse, K.5
Kawahara, M.6
-
15
-
-
78650165390
-
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: Final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124
-
Lara PN Jr, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, et al. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer 2010;116:5710-5.
-
(2010)
Cancer
, vol.116
, pp. 5710-5715
-
-
Lara Jr., P.N.1
Chansky, K.2
Shibata, T.3
Fukuda, H.4
Tamura, T.5
Crowley, J.6
-
16
-
-
33847276516
-
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
-
Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23.
-
(2007)
Ann Oncol
, vol.18
, pp. 317-323
-
-
Ohe, Y.1
Ohashi, Y.2
Kubota, K.3
Tamura, T.4
Nakagawa, K.5
Negoro, S.6
-
17
-
-
56449124059
-
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: A randomised, open-label, phase III study
-
Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008;9:1135-42.
-
(2008)
Lancet Oncol
, vol.9
, pp. 1135-1142
-
-
Kubota, K.1
Kawahara, M.2
Ogawara, M.3
Nishiwaki, Y.4
Komuta, K.5
Minato, K.6
-
18
-
-
33644817804
-
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003
-
Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005;23: 9097-104.
-
(2005)
J Clin Oncol
, vol.23
, pp. 9097-9104
-
-
Williamson, S.K.1
Crowley, J.J.2
Lara Jr., P.N.3
McCoy, J.4
Lau, D.H.5
Tucker, R.W.6
-
19
-
-
0037050354
-
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
-
Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
-
(2002)
N Engl J Med
, vol.346
, pp. 85-91
-
-
Noda, K.1
Nishiwaki, Y.2
Kawahara, M.3
Negoro, S.4
Sugiura, T.5
Yokoyama, A.6
-
20
-
-
66349102227
-
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124
-
Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2530-2535
-
-
Lara Jr., P.N.1
Natale, R.2
Crowley, J.3
Lenz, H.J.4
Redman, M.W.5
Carleton, J.E.6
-
21
-
-
0037673681
-
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors
-
Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003;14:922-30.
-
(2003)
Ann Oncol
, vol.14
, pp. 922-930
-
-
Nakagawa, K.1
Tamura, T.2
Negoro, S.3
Kudoh, S.4
Yamamoto, N.5
Yamamoto, N.6
-
22
-
-
0036842170
-
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
-
Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4292-4302
-
-
Baselga, J.1
Rischin, D.2
Ranson, M.3
Calvert, H.4
Raymond, E.5
Kieback, D.G.6
-
23
-
-
0037106377
-
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial
-
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3815-3825
-
-
Herbst, R.S.1
Maddox, A.M.2
Rothenberg, M.L.3
Small, E.J.4
Rubin, E.H.5
Baselga, J.6
-
24
-
-
0036569870
-
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
-
Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2240-2250
-
-
Ranson, M.1
Hammond, L.A.2
Ferry, D.3
Kris, M.4
Tullo, A.5
Murray, P.I.6
-
25
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]
-
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21:2237-46.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
Tamura, T.4
Nakagawa, K.5
Douillard, J.Y.6
-
26
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
-
Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
-
(2003)
JAMA
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch Jr., T.J.4
Prager, D.5
Belani, C.P.6
-
27
-
-
77950538966
-
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer
-
Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, Horai T, et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2010;30:557-63.
-
(2010)
Anticancer Res
, vol.30
, pp. 557-563
-
-
Takahashi, T.1
Yamamoto, N.2
Nukiwa, T.3
Mori, K.4
Tsuboi, M.5
Horai, T.6
-
28
-
-
33745006872
-
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
-
Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2549-2556
-
-
Ando, M.1
Okamoto, I.2
Yamamoto, N.3
Takeda, K.4
Tamura, K.5
Seto, T.6
-
29
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues, P.J.2
Ciuleanu, T.3
Tan, E.H.4
Hirsh, V.5
Thongprasert, S.6
-
30
-
-
1542503746
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 1
-
Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004;22:777-84.
-
(2004)
J Clin Oncol
, vol.22
, pp. 777-784
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, C.3
Scagliotti, G.4
Rosell, R.5
Miller, V.6
-
31
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 2
-
Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004;22:785-94.
-
(2004)
J Clin Oncol
, vol.22
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
Natale, R.B.4
Miller, V.5
Manegold, C.6
-
32
-
-
24944440830
-
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
-
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
Fehrenbacher, L.4
Johnson, B.E.5
Sandler, A.6
-
33
-
-
34248140107
-
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
-
Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-52.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1545-1552
-
-
Gatzemeier, U.1
Pluzanska, A.2
Szczesna, A.3
Kaukel, E.4
Roubec, J.5
de Rosa, F.6
-
34
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37.
-
(2005)
Lancet
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
Rodrigues, P.J.4
Ciuleanu, T.5
von Pawel, J.6
-
35
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
-
36
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
-
37
-
-
20244388126
-
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
-
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2513-2520
-
-
Mitsudomi, T.1
Kosaka, T.2
Endoh, H.3
Horio, Y.4
Hida, T.5
Mori, S.6
-
38
-
-
27244451321
-
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
-
Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6829-6837
-
-
Takano, T.1
Ohe, Y.2
Sakamoto, H.3
Tsuta, K.4
Matsuno, Y.5
Tateishi, U.6
-
39
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
-
40
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
Sugawara, S.4
Oizumi, S.5
Isobe, H.6
-
41
-
-
75249087060
-
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
-
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
-
(2010)
Lancet Oncol
, vol.11
, pp. 121-128
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
Negoro, S.4
Okamoto, I.5
Tsurutani, J.6
-
42
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
-
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
Feng, J.4
Liu, X.Q.5
Wang, C.6
-
43
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
Vergnenegre, A.4
Massuti, B.5
Felip, E.6
-
44
-
-
84866655838
-
LUX-Lung3: A randomized, open-label phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
-
Abstract LBA7500
-
Yang JCH, Schuler MH, Yamamoto N, O'Byrne KJ, Hirsh V, Mok T, et al. LUX-Lung3: a randomized, open-label phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. ASCO 2012. J Clin Oncol 2012;30(suppl):Abstract LBA7500.
-
(2012)
ASCO 2012. J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Yang, J.C.H.1
Schuler, M.H.2
Yamamoto, N.3
O'Byrne, K.J.4
Hirsh, V.5
Mok, T.6
-
45
-
-
0037025173
-
Cancer. Addiction to oncogenes-The Achilles heal of cancer
-
Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002;297:63-4.
-
(2002)
Science
, vol.297
, pp. 63-64
-
-
Weinstein, I.B.1
-
46
-
-
0034264117
-
Pulmonary drug toxicity: Radiologic and pathologic manifestations
-
Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-59.
-
(2000)
Radiographics
, vol.20
, pp. 1245-1259
-
-
Rossi, S.E.1
Erasmus, J.J.2
McAdams, H.P.3
Sporn, T.A.4
Goodman, P.C.5
-
47
-
-
34247882039
-
Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis
-
Kishi K, Nakata K, Yoshimura K. Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis. J Thorac Oncol 2006;1:733-4.
-
(2006)
J Thorac Oncol
, vol.1
, pp. 733-734
-
-
Kishi, K.1
Nakata, K.2
Yoshimura, K.3
-
48
-
-
2942550603
-
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
-
Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
-
(2004)
Lung Cancer
, vol.45
, pp. 93-104
-
-
Takano, T.1
Ohe, Y.2
Kusumoto, M.3
Tateishi, U.4
Yamamoto, S.5
Nokihara, H.6
-
49
-
-
44949199171
-
Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case-control study
-
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348-57.
-
(2008)
Am J Respir Crit Care Med
, vol.177
, pp. 1348-1357
-
-
Kudoh, S.1
Kato, H.2
Nishiwaki, Y.3
Fukuoka, M.4
Nakata, K.5
Ichinose, Y.6
-
50
-
-
78149448164
-
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer
-
Jones SJ, Milenkova T. ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2010;5:1877-8.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1877-1878
-
-
Jones, S.J.1
Milenkova, T.2
-
51
-
-
58149137203
-
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer
-
Lind JS, Smit EF, Grünberg K, Senan S, Lagerwaard FJ. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. J Thorac Oncol 2008;3:1050-3.
-
(2008)
J Thorac Oncol
, vol.3
, pp. 1050-1053
-
-
Lind, J.S.1
Smit, E.F.2
Grünberg, K.3
Senan, S.4
Lagerwaard, F.J.5
-
52
-
-
35448958809
-
Pulmonary toxicity associated with erlotinib
-
Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, et al. Pulmonary toxicity associated with erlotinib. Chest 2007;132:1042-4.
-
(2007)
Chest
, vol.132
, pp. 1042-1044
-
-
Liu, V.1
White, D.A.2
Zakowski, M.F.3
Travis, W.4
Kris, M.G.5
Ginsberg, M.S.6
-
53
-
-
65349116059
-
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial
-
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
-
(2009)
Lancet
, vol.373
, pp. 1525-1531
-
-
Pirker, R.1
Pereira, J.R.2
Szczesna, A.3
von Pawel, J.4
Krzakowski, M.5
Ramlau, R.6
-
54
-
-
80053573446
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study
-
Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3968-3976
-
-
Ohtsu, A.1
Shah, M.A.2
van Cutsem, E.3
Rha, S.Y.4
Sawaki, A.5
Park, S.R.6
-
55
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
-
56
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
Tsao, C.J.4
Qin, S.5
Kim, J.S.6
-
57
-
-
79960805810
-
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
-
Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117-27.
-
(2011)
Eur J Cancer
, vol.47
, pp. 2117-2127
-
-
Kudo, M.1
Imanaka, K.2
Chida, N.3
Nakachi, K.4
Tak, W.Y.5
Takayama, T.6
-
58
-
-
84871338714
-
The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase I trial in Japanese patients with metastatic solid tumors
-
Nishina T, Hirashima T, Sugio K, Muro K, Akinaga S, Maeda H, et al. The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: results from phase I trial in Japanese patients with metastatic solid tumors. J Clin Oncol 2011;29:2516.
-
J Clin Oncol
, vol.2011
, pp. 29
-
-
Nishina, T.1
Hirashima, T.2
Sugio, K.3
Muro, K.4
Akinaga, S.5
Maeda, H.6
|